Cargando…

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses

OBJECTIVE: Faciocraniosynostoses (FCS) are malformations affecting the development of the bones of the skull and face, due to the premature closure of one or more craniofacial sutures, mostly secondary to activating Fibroblast Growth Factor Receptor (FGFR) 1–3 mutations. Gain-of-function FGFR3 mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ea, Caroline, Hennocq, Quentin, Picard, Arnaud, Polak, Michel, Collet, Corinne, Legeai-Mallet, Laurence, Arnaud, Éric, Paternoster, Giovanna, Khonsari, Roman Hossein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Full Length Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965158/ https://www.ncbi.nlm.nih.gov/pubmed/35372644 http://dx.doi.org/10.1016/j.bonr.2022.101524

Ejemplares similares

FGFR3 overactivation in the brain is responsible for memory impairments in Crouzon syndrome mouse model
por: Cornille, Maxence, et al.
Publicado: (2022)

An Fgfr3-activating mutation in immature murine osteoblasts affects the appendicular and craniofacial skeleton
por: Biosse Duplan, Martin, et al.
Publicado: (2021)

FGFR3 in Periosteal Cells Drives Cartilage-to-Bone Transformation in Bone Repair
por: Julien, Anais, et al.
Publicado: (2020)

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
por: Demuynck, Benoit, et al.
Publicado: (2020)

OR21-05 Low-dose Infigratinib, An Oral Selective Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, Demonstrates Activity In Murine Models Of Achondroplasia And Hypochondroplasia
por: Muslimova, Elena, et al.
Publicado: (2023)

A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis
por: Bi, Yanran, et al.
Publicado: (2023)

Injuries and child abuse increase during the pandemic over 12942 emergency admissions
por: Hennocq, Quentin, et al.
Publicado: (2022)

Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice
por: Loisay, Léa, et al.
Publicado: (2023)

New Insight on FGFR3-Related Chondrodysplasias Molecular Physiopathology Revealed by Human Chondrocyte Gene Expression Profiling
por: Schibler, Laurent, et al.
Publicado: (2009)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Convolutional mesh autoencoders for the 3-dimensional identification of FGFR-related craniosynostosis
por: O’ Sullivan, Eimear, et al.
Publicado: (2022)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients
por: Morice, Anne, et al.
Publicado: (2023)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Safety and feasibility of outpatient ACDF in an ambulatory setting: A retrospective chart review
por: Tally, William C., et al.
Publicado: (2013)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study
por: Nan, Hongmei, et al.
Publicado: (2009)

Role of Postnatal Expression of Fgfr1 and Fgfr2 in Testicular Germ Cells on Spermatogenesis and Fertility in Mice
por: Li, Shengqiang, et al.
Publicado: (2014)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province
por: Jiang, Yongdong, et al.
Publicado: (2015)

Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3
por: Kawane, Tetsuya, et al.
Publicado: (2018)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
por: Lu, Hengyu, et al.
Publicado: (2020)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
por: Sridharan, Vishwajith, et al.
Publicado: (2022)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

Evaluation of Electric Scooter Head and Neck Injuries in Paris, 2017-2019
por: Hennocq, Quentin, et al.
Publicado: (2020)

FGFR2 amplification in colorectal adenocarcinoma
por: Carter, Jamal H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qeue1jhpd6ml30g4ksg7i3vl0e